PCM
BMY icon

Peregrine Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Peregrine Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,561
Closed -$757K – 345
2020
Q3 		$757K Buy
+12,561
New +$756K 0.02% 260

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Peregrine Capital Management's BMY Position: Q4 2020 in Review

Peregrine Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2020, closing a stake of 12,561 shares — an estimated $757K sold.

Peregrine Capital Management first reported a position in BMY in Q3 2020 and held it in 1 quarter. The position peaked at $757K in Q3 2020. 2,359 funds tracked by Wall St. Rank hold BMY as of Q4 2020.

  • Peregrine Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2020 after selling out during the quarter.
  • Peregrine Capital Management sold 12,561 Bristol-Myers Squibb shares in Q4 2020, an estimated $757K.
  • Peregrine Capital Management first reported a position in Bristol-Myers Squibb in Q3 2020 and held it in 1 quarter.
  • Peregrine Capital Management's Bristol-Myers Squibb position peaked at $757K in Q3 2020.
  • 2,359 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2020.

Based on Peregrine Capital Management's 13F filing for Q4 2020, filed 19 Jan 2021.